Anemia in Chronic Kidney Disease
Conditions
Brief summary
Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.
Detailed description
Anemia adversely affects the quality of life of CKD patients and increases the risk of CKD progression. This study utilize data from approximately 20 medical centers across China. It aims to: 1. Analyze the disease characteristics, current diagnostic and treatments in Chinese patients with CKD-anemia. 2. Evaluate the safety and efficacy profiles of different drugs used for CKD-anemia. 3. Explore the direct medical costs associated with CKD-anemia management within real-world clinical practice in China.
Interventions
None listed
Sponsors
Wei Chen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
CKD patients will be defined as those meeting any of the following criteria during the observation period: 1. diagnosis of CKD (e.g., %chronic kidney disease%, %chronic nephropathy%, %renal failure%, %nephritis% for complete ICD-9/10 code mapping\*) 2. record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms) 3. ≥2 eGFR measurements \<60 mL/min/1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)
Exclusion criteria
1. Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia); 2. Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity; 3. Incomplete critical data elements (including age, sex, or visit dates).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China. | 20230101-20241231 | Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage. |
| Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.) | 20230101-20241231 | An analysis will be performed to assess the safety according to CTCAE 5.0 . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analyze the efficacy of different anemia drugs in CKD patients with anemia. | 20230101-20241231 | Use the hemoglobin level to analyze the efficacy of different anemia drugs in CKD patients with anemia. |
| Explore the economic burden of anemia in CKD patients | 20230101-20241231 | Use the annual cost to explore the direct economic burden of anemia in CKD patients. |
Countries
China
Contacts
Primary ContactWei Chen
Backup ContactZhong Zhong
Outcome results
None listed